Tingling in Hands and Feet on Mounjaro: Causes, Evidence and What to Do

What the clinical programme and prescribing information actually say

The SURMOUNT-1 trial, which randomised 2,539 adults with obesity over 72 weeks, was one of the most detailed evaluations of tirzepatide outside diabetes care. Peripheral tingling or neuropathy-like symptoms were not identified as a common adverse event in that dataset. The NHS patient information page for tirzepatide lists the main side effects as gastrointestinal (nausea, vomiting, diarrhoea, constipation and indigestion) along with fatigue, headache and injection-site reactions. Tingling in the extremities does not appear on the standard common-effects list.

That absence does not mean the symptom is imaginary. Post-marketing surveillance and prescriber reports have captured it in a subset of patients. The Mounjaro Summary of Product Characteristics, hosted on the electronic Medicines Compendium, remains the authoritative reference for the complete adverse-event profile; anyone on treatment who experiences unexpected neurological symptoms should review their Patient Information Leaflet and speak to their prescriber. Tingling that is new, worsening or accompanied by other neurological signs should never be left unreported.

The neuropathy connection in people already living with diabetes

For patients taking Mounjaro to manage type 2 diabetes alongside their weight, tingling in the hands and feet carries a specific clinical context. Peripheral neuropathy (nerve damage caused by years of elevated blood glucose) affects a significant proportion of people with long-standing diabetes. When tirzepatide substantially lowers blood sugar levels, as it reliably does, previously masked or subclinical nerve pain can surface or shift in character. This is sometimes called treatment-induced neuropathy of diabetes, and while it is genuinely uncomfortable, it is a known consequence of effective glucose control rather than a sign the medicine is harming the nerves directly.

The pattern typically appears in the first weeks of meaningful glycaemic improvement and tends to stabilise. Letting your prescriber know is important because they can confirm the likely cause, rule out other explanations and decide whether any adjustment is needed. There is useful background on how GLP-1 medicines interact with metabolic conditions on our tirzepatide overview page if you want more context on the mechanism.

Dehydration, electrolytes and the GI side-effect link

Nausea is among the most commonly reported experiences during the early weeks of Mounjaro treatment, especially around dose increases. When nausea leads to reduced eating and drinking, electrolyte levels (sodium, potassium, magnesium) can dip enough to produce tingling, muscle cramps or pins and needles in the periphery. This is a well-understood consequence of poor fluid and nutrient intake rather than a direct drug effect on the nerves.

Practical steps matter here: small frequent sips of fluid, electrolyte-containing drinks if oral intake has been very low, and eating even when appetite is suppressed (protein-rich foods in small amounts are often better tolerated). If vomiting has been persistent for more than a day or two, getting medical advice is sensible, dehydration that leads to kidney strain is one of the more serious GI-adjacent risks the MHRA has highlighted in its GLP-1 safety communications. Our page on whether Mounjaro can cause numbness and tingling goes into the dehydration pathway in more detail.

Cold extremities, circulation and when to get medical help

Some people describe what they call tingling but is closer to a cold, prickling or numb feeling specifically in the fingers and toes, and our dedicated page on Mounjaro hands looks at why this area of the body is so commonly mentioned by people on treatment. There is a dedicated page on whether Mounjaro causes cold hands and feet that separates this from classic tingling and explains what is known about circulation changes on treatment.

As a general rule, tingling that is mild, appeared shortly after starting or increasing a dose, and is improving deserves monitoring and a mention at your next clinical review. Tingling that is severe, involves weakness, started after a fall or injury, is spreading, or does not settle within a couple of weeks needs prompt medical attention. Sudden or one-sided neurological symptoms (numbness in the face, arm or leg with no obvious cause) should prompt a call to 111 or emergency services. For ongoing concerns about how the medicine is sitting with your body, the team at our aftercare line is available seven days a week.

If you are considering Mounjaro and want to understand the full side-effect profile before starting, it is worth looking at the broader Mounjaro treatment page, which covers everything from how the medicine works to what clinical oversight looks like in practice. Cost and what a private prescription typically includes are covered on our Mounjaro prices page. When you are ready to have your medical history reviewed by a prescriber, starting a free consultation is the next step, a real clinician reads your answers the same day, not a chatbot.